Zacks: Analysts Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of -$0.63 Per Share
Wall Street brokerages forecast that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will post earnings per share of ($0.63) for the current quarter, according to Zacks. Seven analysts have made estimates for AMAG Pharmaceuticals’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.85). AMAG Pharmaceuticals posted earnings per share of $1.57 in the same quarter last year, which suggests a negative year-over-year growth rate of 140.1%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 1st.
On average, analysts expect that AMAG Pharmaceuticals will report full-year earnings of ($3.44) per share for the current fiscal year, with EPS estimates ranging from ($3.56) to ($3.31). For the next financial year, analysts expect that the firm will report earnings of ($1.54) per share, with EPS estimates ranging from ($3.09) to ($0.47). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.54). The firm had revenue of $146.25 million for the quarter, compared to analysts’ expectations of $156.26 million. AMAG Pharmaceuticals had a negative return on equity of 2.77% and a negative net margin of 36.87%. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.40) earnings per share.
In other AMAG Pharmaceuticals news, CEO William K. Heiden sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the chief executive officer now directly owns 328,015 shares in the company, valued at $8,200,375. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.00% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of AMAG. Swiss National Bank grew its position in AMAG Pharmaceuticals by 13.0% during the first quarter. Swiss National Bank now owns 63,457 shares of the specialty pharmaceutical company’s stock worth $1,279,000 after buying an additional 7,300 shares during the period. ClariVest Asset Management LLC acquired a new position in AMAG Pharmaceuticals during the first quarter worth about $1,585,000. Northern Trust Corp grew its position in AMAG Pharmaceuticals by 1.0% during the first quarter. Northern Trust Corp now owns 458,445 shares of the specialty pharmaceutical company’s stock worth $9,237,000 after buying an additional 4,468 shares during the period. Piermont Capital Management Inc. grew its position in AMAG Pharmaceuticals by 664.8% during the first quarter. Piermont Capital Management Inc. now owns 100,270 shares of the specialty pharmaceutical company’s stock worth $2,020,000 after buying an additional 87,160 shares during the period. Finally, Employees Retirement System of Texas grew its position in AMAG Pharmaceuticals by 37.5% during the first quarter. Employees Retirement System of Texas now owns 66,000 shares of the specialty pharmaceutical company’s stock worth $1,330,000 after buying an additional 18,000 shares during the period.
NASDAQ AMAG traded up $0.90 during trading hours on Tuesday, hitting $21.45. 665,700 shares of the stock were exchanged, compared to its average volume of 867,235. The stock has a market capitalization of $711.86 million, a P/E ratio of -3.76 and a beta of 0.48. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $26.10. The company has a quick ratio of 1.95, a current ratio of 2.06 and a debt-to-equity ratio of 0.99.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Recommended Story: Diversification Important in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.